Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.33 |
| ▸ | BTK | Q06187 | 3/20 | 0.31 |
| ▸ | CPT1A | P50416 | 5/20 | 0.31 |
| ▸ | CPT2 | P23786 | 3/20 | 0.31 |
| ▸ | PRCP | P42785 | 2/20 | 0.31 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.31 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.30 |
| ▸ | SCD | O00767 | 1/20 | 0.30 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL833485 | 0.89 | ALDH1A1 (0.40) | — | |
| SCHEMBL205757 | 0.89 | ALDH1A1 (0.40) | — | |
| SCHEMBL934404 | 0.86 | DGAT1 (0.32) | DGAT1BTKCPT1ACPT2PRCP | |
| SCHEMBL933195 | 0.86 | MAPT (0.32) | DGAT1CPT1ACPT2PRCPSCD | |
| SCHEMBL933196 | 0.86 | MAPT (0.32) | DGAT1CPT1ACPT2PRCPSCD | |
| SCHEMBL934406 | 0.86 | DGAT1 (0.32) | DGAT1BTKCPT1ACPT2PRCP | |
| SCHEMBL27978679 | 0.83 | TP53 (0.31) | DGAT1CPT1ACPT2PRCPAADAT | |
| SCHEMBL16499389 | 0.81 | F11 (0.32) | CPT1ACPT2 | |
| SCHEMBL2579925 | 0.81 | F11 (0.36) | DGAT1CPT1ACPT2PRCPCPT1B | |
| SCHEMBL750762 | 0.81 | PLAT (0.34) | DGAT1PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2419433-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-03-11 | — | — | EP | disclosed |
| US-8143414-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2430014-A1 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20110098327-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-28 | — | — | US | disclosed |
| WO-2010132601-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098327-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | DGAT1 757/4885BTK 2654/4885CPT1A 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.